- Home
- CPZ vs STRO Comparison
CPZ vs STRO Comparison
Compare CPZ & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CPZ | STRO |
|---|---|---|
| Founded | 2019 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 298.2M | 94.9M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CPZ | STRO |
|---|---|---|
| Price | $14.69 | $9.07 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | 63.0K | ★ 110.8K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 11.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $105,646,000.00 |
| Revenue This Year | N/A | $62.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.17 | $5.23 |
| 52 Week High | $16.11 | $21.90 |
Technical Indicators
Market Signals| Indicator | CPZ | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 36.38 | 77.00 |
| Support Level | $14.50 | $9.53 |
| Resistance Level | $14.88 | $10.10 |
| Average True Range (ATR) | 0.20 | 0.78 |
| MACD | 0.01 | 0.36 |
| Stochastic Oscillator | 32.20 | 89.12 |
Price Performance
Historical ComparisonAbout CPZ Calamos Long/Short Equity & Dynamic Income Trust
Calamos L/S Equity & Dynamic Inc Trust is a trust company which seeks to provide current income and risk-managed capital appreciation. The company invests in securities across sectors such as Industrials, Healthcare, Financials, Consumer Discretionary and others.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.